Intra-Cellular Therapies Current Ratio 2013-2021 | ITCI
For a detailed definition, formula and example for Current Ratio, check out our new background page here.
Intra-Cellular Therapies current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Intra-Cellular Therapies Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2021-06-30 |
$0.60B |
$0.05B |
11.93 |
| 2021-03-31 |
$0.65B |
$0.04B |
16.35 |
| 2020-12-31 |
$0.69B |
$0.04B |
18.75 |
| 2020-09-30 |
$0.75B |
$0.04B |
19.59 |
| 2020-06-30 |
$0.42B |
$0.04B |
10.40 |
| 2020-03-31 |
$0.46B |
$0.03B |
14.83 |
| 2019-12-31 |
$0.23B |
$0.04B |
6.36 |
| 2019-09-30 |
$0.26B |
$0.03B |
7.77 |
| 2019-06-30 |
$0.29B |
$0.03B |
8.87 |
| 2019-03-31 |
$0.32B |
$0.03B |
9.59 |
| 2018-12-31 |
$0.36B |
$0.04B |
9.79 |
| 2018-09-30 |
$0.38B |
$0.03B |
13.16 |
| 2018-06-30 |
$0.41B |
$0.02B |
21.64 |
| 2018-03-31 |
$0.44B |
$0.02B |
22.55 |
| 2017-12-31 |
$0.47B |
$0.01B |
33.02 |
| 2017-09-30 |
$0.33B |
$0.01B |
28.08 |
| 2017-06-30 |
$0.35B |
$0.01B |
50.10 |
| 2017-03-31 |
$0.37B |
$0.02B |
22.77 |
| 2016-12-31 |
$0.39B |
$0.01B |
36.86 |
| 2016-09-30 |
$0.54B |
$0.14B |
3.85 |
| 2016-06-30 |
$0.45B |
$0.02B |
23.05 |
| 2016-03-31 |
$0.46B |
$0.01B |
51.74 |
| 2015-12-31 |
$0.48B |
$0.01B |
77.15 |
| 2015-09-30 |
$0.51B |
$0.01B |
49.32 |
| 2015-06-30 |
$0.21B |
$0.01B |
22.82 |
| 2015-03-31 |
$0.24B |
$0.02B |
16.21 |
| 2014-12-31 |
$0.13B |
$0.01B |
12.41 |
| 2014-09-30 |
$0.14B |
$0.00B |
38.43 |
| 2014-06-30 |
$0.14B |
$0.00B |
51.55 |
| 2014-03-31 |
$0.15B |
$0.00B |
37.42 |
| 2013-12-31 |
$0.04B |
$0.01B |
5.60 |
| 2013-09-30 |
$0.05B |
$0.01B |
6.06 |
| 2013-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2013-03-31 |
$0.00B |
$0.00B |
0.16 |
| 2012-12-31 |
$0.00B |
|
0.00 |
| 2012-09-30 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.590B |
$0.023B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
